Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypercholesterolemia and Hyperlipidemia Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

NCT01911390
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bean powder, Rice bran, Control arm, Bean powder and rice bran
Dietary Supplement
Lead sponsor
Poudre Valley Health System
Other
Eligibility
8 Years to 13 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

NCT02304484
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 1, 2026, 8:47 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Recruiting Phase 1 Interventional

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770
View directory record Official record
Conditions
Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Interventions
VERVE-201
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Port Orange, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

NCT00143676
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and atorvastatin, Atorvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
78
States / cities
Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 1, 2026, 8:47 PM EDT
Not listed Not applicable Interventional

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia, HoFH
Interventions
HDL Therapeutics PDS-2 System
Device
Lead sponsor
HDL Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 1, 2026, 8:47 PM EDT
Active, not recruiting Not applicable Interventional

Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

NCT06065098
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Diabetes, Hypercholesterolemia
Interventions
Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Completed No phase listed Observational

Genetic Influences on Statin Blood Concentrations in African Americans

NCT01569867
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 1, 2026, 8:47 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
17,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
271
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

NCT01979601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LGT209, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

NCT02043301
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bococizumab (PF-04950615; RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Anaheim, California • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 1, 2026, 8:47 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
zodasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

NCT00463606
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT02963311
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
ALN-PCSSC, Standard of Care
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Tailored Communication to Reduce Cardiovascular Risk

NCT01286311
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Artery Disease, Dyslipidemia, Hypertension
Interventions
Direct-to-patient tailored cardiovascular risk message system
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Phytosterols, Ezetimibe, and Cholesterol Metabolism

NCT00863265
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Ezetimibe, Phytosterols + ezetimibe, Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 1, 2026, 8:47 PM EDT
Enrolling by invitation Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SC
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
141
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

NCT02374047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, CAT-2054-C, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

NCT05787002
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 1, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 1, 2026, 8:47 PM EDT